Prosthetic manufacturer Steplife has started collecting applications for participation in the Pre-IPO. Company expects to raise ₽200 million with a post-money valuation of ₽2.2 billion. Funds received will be used to launch the production of a new generation of bionic prostheses. IPO is planned either when the company reaches a valuation of ₽20 billion, or when EBITDA increases to ₽2 billion, which is projected by the end of 2029. A sale option is provided for investors, which is linked to the achievement of targets.